Clinical Trial Update: Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating gadolinium-based contrast agents with ferumoxytol-enhanced MRI to diagnose abnormalities in the central nervous system; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Central Nervous System Neoplasms
• Cranial Nerve Disorders

Drugs mentioned

• FERUMOXYTOL (ferumoxytol)
• Gadolinium-based contrast agent (gadolinium-based contrast agent)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Central Nervous System Neoplasm, Cranial Nerve Disorder | Phase 2 | Status: RECRUITING